Standardisation of von Willebrand Factor in Therapeutic Concentrates: Calibration of the 1st International Standard for von Willebrand Factor Concentrate (00/514)

Summary

An international study involving 26 laboratories assayed two candidate von Willebrand Factor (VWF) concentrates (B and C) for VWF:Antigen (VWF:Ag), VWF:Ristocetin Cofactor (VWF:RCo) and VWF:Collagen binding (VWF:CB) relative to the 4th International Standard Factor VIII/VWF Plasma (4th IS Plasma) (97/586). Estimates of VWF:Ag showed good agreement between different methods, for both candidates, and the overall combined means were 11.01 IU/ml with inter-laboratory variability (GCV) of 10.9% for candidate B and 14.01 IU/ml (GCV 11.8%) for candidate C. Estimates of VWF:RCo showed no significant difference between methods for both candidates and gave overall means of 9.38 IU/ml (GCV 23.7%) for candidate B and 10.19 IU/ml (GCV 24.4%) for candidate C. Prior to the calibration of the candidates for VWF:CB it was necessary to calibrate the 4th IS Plasma relative to local frozen normal plasma pools; there was good agreement between different collagen reagents and an overall mean of 0.83 IU per ampoule (GCV 11.8%) was assigned. In contrast, estimates of VWF:CB in both candidates showed large differences between collagen reagents with inter-laboratory GCV’s of 40%. Candidate B (00/514) was established as the 1st International Standard von Willebrand Factor Concentrate by the WHO Expert Committee on Biological Standardisation in November 2001 with assigned values for VWF:Ag (11.0 IU/ampoule) and VWF:RCo (9.4 IU/ampoule). Large inter-laboratory variability of estimates precluded the assignment of a value for VWF:CB.

Keywords

von Willebrand Factor - von Willebrand Disease - International Standard - Factor VIII concentrates

• References

• 1 Mannucci PM. Treatment of von Willebrand disease. Thromb Haemost 2001; 86: 149-53.
• 2 Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. Prog Hemost Thromb 1986; 08: 19-45.
• 3 Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand Disease. Vox Sanguinis 1992; 62: 193-9.
• 4 Berntorp E. Plasma product treatment in various types of von Willebrand’s disease. Haemostasis 1994; 24: 289-97.
• 5 Menache D, Aronson DL. New treatments of von Willebrand Disease: plasma derived von Willebrand factor concentrates. Thromb Haemost 1997; 78: 566-70.
• 6 Chang AC, Rick ME, Ross LPierce, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 04 (Suppl. 03) 1-6.
• 7 Berndt MC, Du X, Booth WJ. Ristocetin-dependent reconstitution of binding of von Willebrand Factor to purified human platelet membrane glycoprotein Ib-IX complex. Biochemistry 1988; 27: 633-40.
• 8 Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
• 9 Favaloro EJ, Smith J, Petinos P, Hertzberg M, Koutts J. Laboratory testing for von Willebrand’s disease: an assessment of current practice and efficacy by means of a multi-laboratory survey. Thromb Haemost 1999; 82: 1276-82.
• 10 Favaloro EJ. Collagen binding assay for von Willebrand Factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83: 127-35.
• 11 Lawrie AS, Harrison P, Armstrong AL, Wilbourn BR, Dalton RG, Savidge GF. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates. Br J Haematol 1989; 73: 100-4.
• 12 Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand’s disease type III. Ann Hematol 1992; 65: 253-9.
• 13 Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130-7.
• 14 Fricke WA, Lamb MA, Rastogi SC. Standards for assay of von Willebrand Factor concentrates: a collaborative study. Thromb Haemost 1993; 70: 351-6.
• 15 Chang P, Aronson DL. Plasma derived von Willebrand Factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost 1997; 78: 930-3.
• 16 Mannucci PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand Factor in Therapeutic Plasma Concentrates. Blood 1994; 83: 3018-27.
• 17 Hubbard AR, Rigsby P, Barrowcliffe TW. Standardisation of Factor VIII and von Willebrand Factor in plasma: calibration of the 4th International Standard (97/586). Thromb Haemost 2001; 85: 634-9.
• 18 Chang AC, Hubbard AR, Mazurier C. Development of the first international standard for von Willebrand factor (vWF) concentrates. Blood 2000; 96 (11) 2434.
• 19 Campbell PJ. International biological standards and reference preparations. Preparation and presentation of materials to serve as standards and reference preparations. J Biol Standardisation 1974; 02: 249-67.
• 20 Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand Factor activity detected in a monoclonal antibody based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.
• 21 Finney DJ. Statistical methods in biological assay. 3rd ed. Charles Griffin; London: 1978
• 22 Altman DG. Practical statistics for medical research. 1st ed. London: Chapman and Hall; 1991
• 23 Kirkwood TBL. Geometric means and measures of dispersion. Biometrics 1979; 35: 908-9.
• 24 Kirkwood TBL, Tydeman MS. Design and analysis of accelerated degradation tests for the stability of biological standards II. A flexible computer program for data analysis. J Biol Standardisation 1984; 12: 207-14.
• 25 Neugebauer BM, Goy C, Budek I, Seitz R. Comparison of two von Willebrand factor collagen binding assays with different binding affinities for low, medium and high multimers of von Willebrand Factor. Semin Thromb Haemost 2002; 28: 139-47.